CA
OVID icon

CHI Advisors’s Ovid Therapeutics OVID Stock Holding History

CHI Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.32M Hold
864,822
– – 1.32% 18
2023
Q2 		$2.84M Hold
864,822
– – 0.86% 19
2023
Q1 		$2.23M Hold
864,822
– – 0.59% 17
2022
Q4 		$1.61M Hold
864,822
– – 0.43% 20
2022
Q3 		$1.59M Hold
864,822
– – 0.43% 23
2022
Q2 		$1.86M Buy
864,822
+11,934
+1% +$28.8K 0.71% 23
2022
Q1 		$2.68M Buy
852,888
+452,888
+113% +$1.42M 1.14% 20
2021
Q4 		$1.28M Buy
400,000
+166,490
+71% +$570K 0.43% 18
2021
Q3 		$785K Buy
233,510
+15,000
+7% +$54.7K 0.23% 16
2021
Q2 		$854K Sell
218,510
-29,000
-12% -$114K 0.2% 17
2021
Q1 		$995K Sell
247,510
-579,750
-70% -$1.93M 0.2% 17
2020
Q4 		$1.91M Buy
827,260
+209,168
+34% +$975K 0.54% 12
2020
Q3 		$3.55M Buy
618,092
+73,811
+14% +$494K 1.26% 11
2020
Q2 		$4.01M Sell
544,281
-284,132
-34% -$1.33M 1.57% 8
2020
Q1 		$2.47M Sell
828,413
-15,518
-2% -$52.3K 5.82% 4
2019
Q4 		$3.5M Buy
843,931
+116,671
+16% +$368K 2.64% 4
2019
Q3 		$2.36M Buy
+727,260
New +$1.65M 2.29% 4

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

CHI Advisors's OVID Position: Q3 2023 in Review

CHI Advisors held its Ovid Therapeutics (OVID) position steady in Q3 2023 at 864,822 shares worth $3.32M. The position accounts for 1.32% of the portfolio, ranked #18.

CHI Advisors first reported a position in OVID in Q3 2019 and has held it in 17 quarters since. The position peaked at $4.01M in Q2 2020. 64 funds tracked by Wall St. Rank hold OVID as of Q3 2023.

  • CHI Advisors held 864,822 shares of Ovid Therapeutics worth $3.32M as of Q3 2023.
  • CHI Advisors left its Ovid Therapeutics share count unchanged in Q3 2023.
  • Ovid Therapeutics made up 1.32% of CHI Advisors's portfolio in Q3 2023, its #18 holding.
  • CHI Advisors first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 17 quarters since.
  • CHI Advisors's Ovid Therapeutics position peaked at $4.01M in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.